Does Dr. PHILIPPE GENEREUX have financial conflicts of interest?

Dr. PHILIPPE GENEREUX (M.D.) has received a total of $1,134,843 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $1,133,345 in personal promotional payouts (consulting, meals, travel) and $1,498 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. PHILIPPE GENEREUX?

According to CMS Open Payments data, Dr. PHILIPPE GENEREUX received funding from EDWARDS LIFESCIENCES CORPORATION ($345,211), OPSENS ($318,281), and CARDIVA MEDICAL ($217,311).

Does Dr. PHILIPPE GENEREUX receive research grants or speaking fees?

Dr. PHILIPPE GENEREUX has received $1,133,345 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $1,498 in clinical research grants.

DR. PHILIPPE GENEREUX

M.D.Real-Time Hydrated

Specialty: Internal Medicine, Cardiovascular Disease

Practice Location: NEW YORK, NY 10032

NPI Number: 1114179264

LIFETIME INDUSTRY VALUE

$1,134,843

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. GENEREUX is a verified Internal Medicine, Cardiovascular Disease practitioner based in NEW YORK, NY.

Between 2021 and 2025, Dr. GENEREUX had an overall industry promotional and research financial footprint of $1,134,843 as recorded in the federal CMS Open Payments database.

$1,133,345 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$1,498 was allocated to sponsored clinical trials and medical research activities.

Dr. GENEREUX's primary funding source is EDWARDS LIFESCIENCES CORPORATION, which accounts for $345,211 (representing 30.4% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

EDWARDS LIFESCIENCES CORPORATION

Rank 1

$345,211

30.4%

OPSENS

Rank 2

$318,281

28%

CARDIVA MEDICAL

Rank 3

$217,311

19.1%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.